These fusion chimeras result in increased STAT3 activity and develop ALCL phenotype via STAT3 signaling, suggesting that intercepting STAT3 activation may have a therapeutic advantage (94). The gene discussed is STAT3; the disease is anaplastic large cell lymphoma.